603127 昭衍新药
已收盘 10-15 15:00:00
资讯
新帖
简况
昭衍新药(06127)转仓市值总计2.02亿港元 占比5.43% 从香港上海汇丰银行转出315.73万股
智通财经 · 10-13 08:10
昭衍新药(06127)转仓市值总计2.02亿港元 占比5.43% 从香港上海汇丰银行转出315.73万股
股市必读：昭衍新药（603127）10月12日董秘有最新回复
证券之星 · 10-13 01:15
股市必读：昭衍新药（603127）10月12日董秘有最新回复
一个月内股价上涨超40%，昭衍新药(06127)H股何以走出弹性更强的独立行情？
智通财经 · 10-11
一个月内股价上涨超40%，昭衍新药(06127)H股何以走出弹性更强的独立行情？
摩根士丹利在昭衍新药的H股好仓比例下降1.23%至4.70%
南方财经网 · 10-09
摩根士丹利在昭衍新药的H股好仓比例下降1.23%至4.70%
昭衍新药（603127）10月8日主力资金净买入1.37亿元
证券之星 · 10-09
昭衍新药（603127）10月8日主力资金净买入1.37亿元
10月8日昭衍新药涨5.60%，广发医疗保健股票A基金重仓该股
证券之星 · 10-08
10月8日昭衍新药涨5.60%，广发医疗保健股票A基金重仓该股
昭衍新药午后涨逾4% 华泰证券维持“买入”评级
新浪港股 · 10-08
昭衍新药午后涨逾4% 华泰证券维持“买入”评级
诺奖光遗传学技术引产业关注，国内多条神经基因治疗管线加速推进
中金财经 · 10-06
诺奖光遗传学技术引产业关注，国内多条神经基因治疗管线加速推进
摩根士丹利在昭衍新药的H股好仓比例上升0.39%至5.23%
南方财经网 · 10-05
摩根士丹利在昭衍新药的H股好仓比例上升0.39%至5.23%
广发基金管理有限公司增持昭衍新药(06127)40.92万股 每股作价约28.68港元
智通财经 · 09-30
广发基金管理有限公司增持昭衍新药(06127)40.92万股 每股作价约28.68港元
9月30日昭衍新药涨10.00%，广发医疗保健股票A基金重仓该股
证券之星 · 09-30
9月30日昭衍新药涨10.00%，广发医疗保健股票A基金重仓该股
港股午评|恒生指数早盘跌0.04% CRO概念股涨幅居前
智通财经 · 09-30
港股午评|恒生指数早盘跌0.04% CRO概念股涨幅居前
异动快报：昭衍新药（603127）9月30日10点49分触及涨停板
证券之星 · 09-30
异动快报：昭衍新药（603127）9月30日10点49分触及涨停板
昭衍新药（603127）披露2026年中期报告，9月29日股价下跌1.36%
证券之星 · 09-29
昭衍新药（603127）披露2026年中期报告，9月29日股价下跌1.36%
昭衍新药（603127）9月23日主力资金净买入1.25亿元
证券之星 · 09-24
昭衍新药（603127）9月23日主力资金净买入1.25亿元
昭衍新药：认购中信证券金融产品 投资金额5.4亿元
南方财经网 · 09-23
昭衍新药：认购中信证券金融产品 投资金额5.4亿元
CRO概念股早盘多数走高 金斯瑞生物科技及昭衍新药均涨超4%
新浪港股 · 09-23
CRO概念股早盘多数走高 金斯瑞生物科技及昭衍新药均涨超4%
医药外包概念盘初走高 昭衍新药（06127）涨6.14% 机构指CXO为医药行业中最亮眼板块之一
金吾财讯 · 09-21
医药外包概念盘初走高 昭衍新药（06127）涨6.14% 机构指CXO为医药行业中最亮眼板块之一
港股午评|恒生指数早盘涨0.67% AI制药板块大涨
智通财经 · 09-18
港股午评|恒生指数早盘涨0.67% AI制药板块大涨
CXO板块上扬 昭衍新药（06127）涨5.64%、金斯瑞生物科技（01548）涨4.78%
金吾财讯 · 09-18
CXO板块上扬 昭衍新药（06127）涨5.64%、金斯瑞生物科技（01548）涨4.78%
暂无数据
公司概况
公司名称：
北京昭衍新药研究中心股份有限公司
所属行业：
研究和试验发展
上市日期：
2017-08-25
主营业务：
北京昭衍新药研究中心股份有限公司的主营业务是提供药物非临床研究服务。公司的主要产品是非临床评价服务和药物发现服务、临床试验全流程服务、专业临床检测服务、实验模型研究。
发行价格：
12.51
{"stockData":{"symbol":"603127","market":"SH","secType":"STK","nameCN":"昭衍新药","latestPrice":50.65,"timestamp":1792047600000,"preClose":48.79,"halted":0,"volume":46776708,"delay":0,"changeRate":0.0381,"floatShares":628000000,"shares":749000000,"eps":1.3138,"marketStatus":"已收盘","change":1.86,"latestTime":"10-15 15:00:00","open":47.9,"high":52.61,"low":47.55,"amount":2369000000,"amplitude":0.1037,"askPrice":50.65,"askSize":835,"bidPrice":50.64,"bidSize":21,"shortable":0,"etf":0,"ttmEps":1.3138,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792114200000},"marketStatusCode":5,"adr":0,"adjPreClose":48.79,"symbolType":"stock","openAndCloseTimeList":[[1792027800000,1792035000000],[1792040400000,1792047600000]],"highLimit":53.67,"lowLimit":43.91,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":749348220,"isCdr":false,"pbRate":4.23,"roa":"--","peRate":38.552291,"roe":"8.61%","epsLYR":0.4,"committee":-0.734331,"marketValue":37954000000,"turnoverRate":0.0745,"status":0,"hkstockBrief":{"symbol":"06127","market":"HK","secType":"STK","nameCN":"昭衍新药","latestPrice":28.16,"timestamp":1792051715009,"preClose":28.12,"halted":0,"volume":6949578,"delay":0,"premium":"-52.60"},"floatMarketCap":31794000000},"requestUrl":"/m/hq/s/603127/tweets","defaultTab":"tweets","newsList":[{"id":"2675385097","title":"昭衍新药(06127)转仓市值总计2.02亿港元 占比5.43% 从香港上海汇丰银行转出315.73万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675385097","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675385097?lang=zh_cn&edition=full","pubTime":"2026-10-13 08:10","pubTimestamp":1791850253,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，10月12日，昭衍新药(06127)出现仓位异动，转仓市值总计2.02亿港元，占比5.43%。该公司股东向摩根士丹利香港证券转入302.68万股，从香港上海汇丰银行转出315.73万股。华泰证券此前指出，公司上半年整体在手订单金额约37亿元，同比增长60.9%，新签订单金额约20.2亿元，同比增长98.0%，其中2Q26新签订单金额约11.1亿元，订单表现持续亮眼，后续业绩能见度进一步提升。考虑国内行业需求积极回暖，叠加公司海外业务持续拓展，看好公司业务中长期成长空间。公司A、H股均维持“买入”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1506241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1610","BK1601","HSBA.UK","LU1267930227.SGD","00005","BK1231","LU0149721374.USD","IE0008369823.USD","LU0310800965.SGD","HSBH","LU0496365809.HKD","LU0918141705.HKD","BK4521","603127","LU0345776255.USD","LU0348814723.USD","LU0128525689.USD","LU0211326755.USD","LU0516423091.SGD","LU0516422440.USD","BK1576","LU0052756011.USD","LU0634319403.HKD","BK4585","LU0516422366.SGD","LU2449936058.SGD","LU0797268264.HKD","LU0345775950.USD","LU0976567544.SGD","LU0417516738.SGD","HSHD.SI","LU0164880469.USD","LU2226246903.HKD","BK4207","06127","LU0540923850.HKD","BK1141","LU0516422952.EUR","03143","LU1105468828.SGD","LU1282648689.USD","LU0348735423.USD","BK1572","HSBC","LU1770036033.HKD","LU1481107354.HKD","BK0216","LU2236285917.USD","BK4588","LU0516423174.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675801792","title":"股市必读：昭衍新药（603127）10月12日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2675801792","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675801792?lang=zh_cn&edition=full","pubTime":"2026-10-13 01:15","pubTimestamp":1791825317,"startTime":"0","endTime":"0","summary":"截至2026年10月12日收盘，昭衍新药报收于50.73元，下跌3.56%，换手率6.98%，成交量43.82万手，成交额22.96亿元。董秘最新回复投资者： 董秘好，能发布一下最近的股东人数吗？请将个人持股证明等文件发送到公司联系邮箱，或者致电010-67869582，公司核实后进行回复，谢谢。当日关注点交易信息汇总：10月12日主力资金净流出1044.88万元，占总成交额0.46%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300001632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","06127","BK1141","BK0216","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674812812","title":"一个月内股价上涨超40%，昭衍新药(06127)H股何以走出弹性更强的独立行情？","url":"https://stock-news.laohu8.com/highlight/detail?id=2674812812","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674812812?lang=zh_cn&edition=full","pubTime":"2026-10-11 16:58","pubTimestamp":1791709113,"startTime":"0","endTime":"0","summary":"8月28日盘后，昭衍新药发布26H1业绩快报。然而，当昭衍新药在9月29日正式披露26H1财报后，其H股股价却在次日大幅收涨15.62%。从盘面来看，8月10日至9月11日，昭衍新药H股收盘价从26.64港元跌至21.20港元，区间累计跌幅为20.42%。值得一提的是，在9月14日以来的这轮行情中，昭衍新药的H股显示出了更强的弹性。而这在一定程度说明昭衍新药的A股与板块情绪存在联动，但其H股超额收益明显，显示出更强的独立定价特征。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","603127","BK0216","06127","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674783058","title":"摩根士丹利在昭衍新药的H股好仓比例下降1.23%至4.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674783058","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674783058?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:19","pubTimestamp":1791537540,"startTime":"0","endTime":"0","summary":"南财智讯10月9日电，香港交易所披露信息显示，MorganStanley（摩根士丹利）在昭衍新药的H股好仓（L）比例于10月6日从5.93%下降至4.70%。同时淡仓（S）比例从0.94%降至0.91%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610093891327295.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610093891327295.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["603127","BK0216","06127","BK1576","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674867978","title":"昭衍新药（603127）10月8日主力资金净买入1.37亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674867978","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674867978?lang=zh_cn&edition=full","pubTime":"2026-10-09 08:15","pubTimestamp":1791504957,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月8日收盘，昭衍新药报收于52.06元，上涨5.6%，换手率13.31%，成交量83.58万手，成交额43.1亿元。10月8日的资金流向数据方面，主力资金净流入1.37亿元，占总成交额3.18%，游资资金净流入7938.25万元，占总成交额1.84%，散户资金净流出2.16亿元，占总成交额5.02%。融券方面，融券卖出8.26万股，融券偿还1.23万股，融券余量25.01万股，融券余额1302.02万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900005881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","06127","BK1576","BK0216","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673027860","title":"10月8日昭衍新药涨5.60%，广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2673027860","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673027860?lang=zh_cn&edition=full","pubTime":"2026-10-08 16:33","pubTimestamp":1791448436,"startTime":"0","endTime":"0","summary":"证券之星消息，10月8日昭衍新药涨5.60%，收盘报52.06元，换手率13.31%，成交量83.58万手，成交额43.1亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共39家，其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为35.24亿元，最新净值1.8912，较上一交易日上涨2.55%，近一年下跌9.72%。广发医疗保健股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800021187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","06127","BK0216","BK1576","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673284830","title":"昭衍新药午后涨逾4% 华泰证券维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2673284830","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673284830?lang=zh_cn&edition=full","pubTime":"2026-10-08 13:10","pubTimestamp":1791436200,"startTime":"0","endTime":"0","summary":"模拟交易客户端昭衍新药盘中逆势涨超5%，截至发稿，股价上涨3.93%，现报30.66港元，成交额2.09亿港元。华泰证券此前指出，公司上半年整体在手订单金额约37亿元，同比增长60.9%，新签订单金额约20.2亿元，同比增长98.0%，其中2Q26新签订单金额约11.1亿元，订单表现持续亮眼，后续业绩能见度进一步提升。公司A、H股均维持“买入”评级。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-10-08/doc-iniunvxc7578225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603127","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673051766","title":"诺奖光遗传学技术引产业关注，国内多条神经基因治疗管线加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2673051766","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673051766?lang=zh_cn&edition=full","pubTime":"2026-10-06 21:30","pubTimestamp":1791293401,"startTime":"0","endTime":"0","summary":"近日，2026 年诺贝尔生理学或医学奖正式揭晓，表彰科学家在光遗传学领域的开创性研究成果，这项颠覆性底层技术火速出圈，引爆资本市场与生物医药行业关注，带动脑科学、神经基因治疗赛道热度全面攀升。业内人士分析，本次诺奖权威背书，将大幅加速光遗传学技术的科研转化与产业普及，进一步兑现赛道价值。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202610/06/20261006119145.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202610/06/20261006119145.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20261006/32388712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["600196","BK0028","688767","BK0060","BK0188","BK0012","BK0236","BK0187","300683","301293","BK0216","BK0239","BK0196","BK0096","BK0183","603127","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673701356","title":"摩根士丹利在昭衍新药的H股好仓比例上升0.39%至5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673701356","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673701356?lang=zh_cn&edition=full","pubTime":"2026-10-05 18:04","pubTimestamp":1791194662,"startTime":"0","endTime":"0","summary":"南财智讯10月5日电，香港交易所披露信息显示，MorganStanley（摩根士丹利）在昭衍新药的H股好仓（L）比例于9月29日从4.84%上升至5.23%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610053888651587.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610053888651587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1141","BK1576","BK0216","06127","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671209146","title":"广发基金管理有限公司增持昭衍新药(06127)40.92万股 每股作价约28.68港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671209146","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671209146?lang=zh_cn&edition=full","pubTime":"2026-09-30 19:33","pubTimestamp":1790768009,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，9月24日，广发基金管理有限公司增持昭衍新药(06127)40.92万股，每股作价28.6766港元，总金额约为1173.45万港元。增持后最新持股数目约为611.23万股，最新持股比例为5.14%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","EWH","BK0216","06127","BK1576","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671906274","title":"9月30日昭衍新药涨10.00%，广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2671906274","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671906274?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:33","pubTimestamp":1790757221,"startTime":"0","endTime":"0","summary":"证券之星消息，9月30日昭衍新药涨10.00%，收盘报49.3元，换手率8.83%，成交量55.4万手，成交额26.47亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共39家，其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为35.24亿元，最新净值1.8442，较上一交易日下跌0.02%，近一年下跌9.9%。广发医疗保健股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000025768.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","06127","BK1141","BK0216","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671222053","title":"港股午评|恒生指数早盘跌0.04% CRO概念股涨幅居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2671222053","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671222053?lang=zh_cn&edition=full","pubTime":"2026-09-30 12:00","pubTimestamp":1790740842,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数跌0.04%，跌10个点，报24513点；恒生科技指数跌0.15%。港股早盘成交887亿港元。mRNA概念股涨幅居前。CRO概念股涨幅居前，BD高增叠加湿实验需求升温，行业景气度上行信号明确。泰格医药涨超4%，与迪安诊断签署战略合作协议，将围绕AI制药等多领域开展深度合作。地产港股盘中V型反转，万科企业一度跌超11%，午盘涨超2%。汇量科技涨超8%，AI Infra升级有望进一步提升算法效率。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0244354667.USD","03088","82800","HK0000320223.HKD","BK4548","07226","01860","BK4501","02837","002821","BK4588","BK1524","BK4568","BK1518","BK1198","MCHmain","BK1141","03037","03067","BK1544","BK1137","03033","06127","03423","BK1515","00625","BK1178","03417","BK1555","LGHT","BK4533","BK1592","07300","09067","06821","03115","BK1240","BK1507","02833","URNJ","03347","BK4532","IE0034224299.USD","300347","HK0000306685.HKD","LU0140636845.USD","LU0828237940.HKD","03419","83115","HHImain","01548","07500","MRNX","MRNA","MRNY","BK1586","BK4534","LU1831875114.USD","BK1613","02723","BK1576","06802","688185","07552","GNOM","513600","LU0463099449.HKD","IDNA","BK1590","01787","02362","BK4585","BK4139","07200","BK4551","09115","06185","09088","600547","BK1583","HK0000306701.USD","HSTECH","LU0326950275.SGD","LU1188198961.HKD","WDNA","HK0000320264.USD","603127","HSI","BK1574","BK1206","LU0181495838.USD","03032","02202","BK1161","01164","02800","000002","BK1191","BK1594","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671616224","title":"异动快报：昭衍新药（603127）9月30日10点49分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2671616224","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671616224?lang=zh_cn&edition=full","pubTime":"2026-09-30 10:50","pubTimestamp":1790736646,"startTime":"0","endTime":"0","summary":"证券之星9月30日盘中消息，10点49分昭衍新药（603127）触及涨停板。其所属行业医疗服务目前上涨。领涨股为南模生物。该股为基因编辑，CAR-T疗法，干细胞概念热股，当日基因编辑概念上涨4.9%，CAR-T疗法概念上涨4.28%，干细胞概念上涨3.99%。9月29日的资金流向数据方面，主力资金净流出2856.43万元，占总成交额1.97%，游资资金净流出29.95万元，占总成交额0.02%，散户资金净流入2886.38万元，占总成交额1.99%。近5日资金流向一览见下表：昭衍新药主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000012845.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","06127","603127","BK0216","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671225210","title":"昭衍新药（603127）披露2026年中期报告，9月29日股价下跌1.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671225210","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671225210?lang=zh_cn&edition=full","pubTime":"2026-09-29 22:04","pubTimestamp":1790690667,"startTime":"0","endTime":"0","summary":"截至2026年9月29日收盘，昭衍新药报收于44.82元，较前一交易日下跌1.36%，最新总市值为335.86亿元。该股当日开盘45.05元，最高47.3元，最低44.52元，成交额达14.49亿元，换手率为5.06%。近日，北京昭衍新药研究中心股份有限公司披露2026年中期报告，报告期内实现营业收入7.04亿元，同比增长5.27%；归属于上市公司股东的净利润为7.48亿元，同比增长1126.80%。公司新签订单金额约20.2亿元，同比增长98.0%，在手订单总额约37亿元，同比增长60.9%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900039588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","603127","BK1576","06127","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669322324","title":"昭衍新药（603127）9月23日主力资金净买入1.25亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669322324","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669322324?lang=zh_cn&edition=full","pubTime":"2026-09-24 08:18","pubTimestamp":1790209123,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月23日收盘，昭衍新药报收于47.77元，上涨3.58%，换手率7.96%，成交量49.96万手，成交额23.98亿元。9月23日的资金流向数据方面，主力资金净流入1.25亿元，占总成交额5.22%，游资资金净流出5953.8万元，占总成交额2.48%，散户资金净流出6569.04万元，占总成交额2.74%。融券方面，融券卖出4.1万股，融券偿还100.0股，融券余量26.03万股，融券余额1243.45万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400007716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","BK1141","BK1576","603127","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669910137","title":"昭衍新药：认购中信证券金融产品 投资金额5.4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669910137","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669910137?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:53","pubTimestamp":1790153580,"startTime":"0","endTime":"0","summary":"南财智讯9月23日电，昭衍新药（06127.HK）发布须予披露交易公告，于2026年4月20日至2026年9月23日期间，公司附属公司透过中信证券及其附属公司认购了七项中信证券金融产品，合计投资金额为人民币5.4亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609233882481581.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609233882481581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1997244956.HKD","BK1147","LU2289578879.USD","LU1328615791.USD","LU1064131003.USD","06030","LU2148510915.USD","LU2495084118.USD","06127","BK1521","LU1146622755.USD","LU1997245094.SGD","BK1516","LU1064130708.USD","LU1781817850.SGD","LU1720050803.USD","LU2580892862.HKD","BK1564","BK1141","LU0405327494.USD","159940","BK0183","LU1580142542.USD","BK0216","BK0188","LU2580892789.USD","BK0196","LU1655091616.SGD","BK0028","LU1794554557.SGD","BK1576","600030","LU1820825898.SGD","BK0276","603127","LU0405327148.USD","LU1255011170.USD","BK0012","LU1997245177.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669174258","title":"CRO概念股早盘多数走高 金斯瑞生物科技及昭衍新药均涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669174258","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669174258?lang=zh_cn&edition=full","pubTime":"2026-09-23 11:40","pubTimestamp":1790134800,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端CRO概念股早盘多数走高，截至发稿，金斯瑞生物科技（01548）上涨4.70%，报42.36港元；昭衍新药（06127）上涨4.45%，报27.70港元；康龙化成（03759）上涨2.51%，报31.02港元；泰格医药（03347）上涨0.82%，报46.96港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-23/doc-inisusyi5326555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000320264.USD","BK1583","01548","603127","BK1141","HK0000306685.HKD","06127","HK0000306701.USD","HK0000320223.HKD","BK0216","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669139506","title":"医药外包概念盘初走高 昭衍新药（06127）涨6.14% 机构指CXO为医药行业中最亮眼板块之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2669139506","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669139506?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:10","pubTimestamp":1789956632,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药外包概念盘初走高，截至发稿，昭衍新药（06127）涨6.14%，药明生物（02269）涨4.97%，金斯瑞生物科技（01548）涨4.47%，维亚生物（01873）涨3.75%，药明康德（02359）涨3.40%，泰格医药（03347）涨2.52%，康龙化成（03759）涨2.64%。中邮证券研究指，2026中报看，CXO行业是医药行业中最亮眼板块之一。数据上看，CDMO龙头、安评及临床CRO是三条景气主线。估值上看，CDMO龙头公司按2027PE仍处于合理区间，CRO环节公司报表仍处修复阶段，新签高毛利订单待转化，因此表观估值较高，但预计随着订单的逐渐周转快速消化。","market":"sg","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992050","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0039217434.USD","LU0516422440.USD","09939","01873","603127","03759","BK1610","LU0307460666.USD","LU0359201612.USD","LU0540923850.HKD","LU0051755006.USD","BK1583","LU0359202008.SGD","LU1794554557.SGD","LU0456846285.SGD","LU0043850808.USD","LU0561508036.HKD","KURE","02269","LU0029874905.USD","LU0348766576.USD","LU1880383366.USD","SG9999002463.SGD","LU0348825331.USD","LU3063872942.SGD","BK1589","CXO","06127","03347","HK0000306701.USD","LU0516422366.SGD","BK1515","LU0181495838.USD","WX","02359","BK1141","BK1161","HK0000320223.HKD","LU0029874061.USD","LU1242518857.USD","LU0052750758.USD","LU0320764599.SGD","159938","LU0516422952.EUR","LU2125910500.SGD","LU2242644610.SGD","LU0516423091.SGD","01548","LU0588546209.SGD","LU0516423174.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668191239","title":"港股午评|恒生指数早盘涨0.67% AI制药板块大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2668191239","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668191239?lang=zh_cn&edition=full","pubTime":"2026-09-18 12:00","pubTimestamp":1789704004,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数涨0.67%，涨164点，报24768点；恒生科技指数涨1.74%。港股早盘成交1070亿港元。十部门印发医药十五五规划，机构看好医药迎“Claude”时刻。AI制药进入战略入局阶段。曦智科技-P涨超17%。天数智芯涨超13%，公司有望持续受益AI资本开支的增长及算力自主可控浪潮。MINIMAX-W涨13%，旗下多款产品通过Singtel AI Pass纳入配套订阅计划。俊知集团涨超10%，收购青海中利光纤技术有望打开AI算力相关光纤产品增量空间。大股东解禁期满。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02701","LU0791591158.USD","LU0890818403.SGD","BK1574","LU0572940350.SGD","LU0572939691.SGD","07200","BK1183","02142","82800","03115","TCHI","03696","LU0244354667.USD","513600","02228","LU0543330483.HKD","BK1592","83115","LU1366334578.USD","02833","09067","00992","BK1117","IE00B0JY6N72.USD","BK1576","LU1235295612.USD","LU1366334651.USD","LU0049112450.USD","02837","03033","02656","BK1237","300077","HK0000306701.USD","BK1198","LU0140636845.USD","LU2242644610.SGD","HK0000320264.USD","02670","BK1544","LU0128525689.USD","80992","LU0048580855.USD","LU1831875114.USD","LU0029875118.USD","BK1506","LU0052756011.USD","07500","LU0417516902.SGD","HK0000306685.HKD","LU0862451837.USD","06658","02800","LU0320764755.SGD","LU0310800965.SGD","07226","01879","01818","HHImain","LU1046422090.SGD","HK0000320223.HKD","BK1193","07300","IE0003895053.USD","07552","09903","LU0181495838.USD","03067","BK1197","LU1785774172.SGD","BK1161","06127","07666","LNVGY","LU0463099449.HKD","03417","BK1149","LU0791590937.USD","01300","03423","07630","03032","BK1607","HSTECH","LU1267930227.SGD","IE0032431581.USD","09115","LU1188198961.HKD","LU0561508036.HKD","LU0264606111.USD","LU0828237940.HKD","LU0672654166.SGD","01787","LU0326950275.SGD","BK1617","LU0370786039.SGD","BK1141","09088","IE0034224299.USD","MCHmain","03037","LU0348827113.USD","LU0972618739.USD","LU0348825331.USD","LU0862451753.SGD","600547","603127","LU0128522157.USD","BK1163","HSI","00100","BK1583","03088","03419","BK1526","LU1808992512.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668919819","title":"CXO板块上扬 昭衍新药（06127）涨5.64%、金斯瑞生物科技（01548）涨4.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668919819","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668919819?lang=zh_cn&edition=full","pubTime":"2026-09-18 09:46","pubTimestamp":1789695974,"startTime":"0","endTime":"0","summary":"金吾财讯 | CXO板块上扬，昭衍新药 涨5.64%，金斯瑞生物科技涨4.78%，维亚生物涨2.15%，泰格医药涨1.93%，药明生物涨1.80%，凯莱英涨1.79%，药明康德涨1.01%，百济神州涨0.95%。中信建投近日研报指，CXO是创新药产业链专业化分工的重要载体，也是连接药物研发与商业化生产的关键基础设施。随着内外需改善逐步传导至订单与业绩，CXO有望进入新一轮增长阶段。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991930","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029874905.USD","BK1610","LU3063872942.SGD","LU1880383366.USD","LU0181495838.USD","LU0588546209.SGD","LU1251922891.USD","IE00B0JY6N72.USD","WX","LU0348827113.USD","01873","LU0469268626.HKD","LU1242518931.SGD","LU0516423174.USD","LU0320764243.SGD","LU0456846285.SGD","CXO","LU0634319403.HKD","06160","LU0228659784.USD","LU1719994722.HKD","LU0039217434.USD","03347","LU0348825331.USD","LU0052750758.USD","SG9999002562.SGD","603127","LU0029874061.USD","LU0051755006.USD","02359","06127","LU0320764599.SGD","01548","LU2242644610.SGD","KURE","LU0128522744.USD","BK1588","02269","LU2039709279.SGD","BK1521","LU0359202008.SGD","LU0828237510.HKD","LU1242518857.USD","06821","BK1161","BK0216","LU0561508036.HKD","LU0856984785.SGD","LU1688375341.USD","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792059836772,"stockEarnings":[{"period":"1week","weight":-0.0103},{"period":"1month","weight":0.14},{"period":"3month","weight":-0.0838},{"period":"6month","weight":0.3251},{"period":"1year","weight":0.5302},{"period":"ytd","weight":0.3978}],"compareEarnings":[{"period":"1week","weight":-0.0195},{"period":"1month","weight":-0.0304},{"period":"3month","weight":-0.0297},{"period":"6month","weight":-0.0701},{"period":"1year","weight":-0.0254},{"period":"ytd","weight":-0.0508}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京昭衍新药研究中心股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"0人","perCapita":"--","listingDate":"2017-08-25","address":"北京市大兴区北京经济技术开发区荣京东街甲5号","registeredCapital":"74934万元","survey":" 北京昭衍新药研究中心股份有限公司的主营业务是提供药物非临床研究服务。公司的主要产品是非临床评价服务和药物发现服务、临床试验全流程服务、专业临床检测服务、实验模型研究。","listedPrice":12.51},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昭衍新药(603127)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昭衍新药(603127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昭衍新药,603127,昭衍新药股票,昭衍新药股票老虎,昭衍新药股票老虎国际,昭衍新药行情,昭衍新药股票行情,昭衍新药股价,昭衍新药股市,昭衍新药股票价格,昭衍新药股票交易,昭衍新药股票购买,昭衍新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昭衍新药(603127)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昭衍新药(603127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}